Teva Pharmaceutical Industries, a global generic drug maker, has acquired Cephalon.

Following the merger agreement between the parties, each share of Cephalon common stock has been converted into the right to receive $81.50 in cash.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Teva president and CEO Shlomo Yanai said the deal would strengthen their specialty pharmaceuticals business through diversification and expansion of their product.

"Our newly-expanded portfolio in CNS, Oncology, Respiratory and Women’s Health, along with our robust pipeline of more than 30 late-stage products truly cements our position as a leader in specialty pharma," Yanai added.

Teva expects the acquisition to be immediately accretive to Teva’s non-GAAP earnings per share and accretive to Teva’s GAAP earnings within the fourth quarter of closing.

 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now